British Biotech's Falling Star
Only a couple of years ago, Keith G. McCullagh looked like Britain's gift to genetic engineering. British Biotech PLC, which McCullagh co-founded in 1986, had enough promise to set investors aglow--and it did. In 1992, it became the first biotechnology concern in Europe to go public. Four years later, the market valued McCullagh's once struggling startup at $2.85 billion, ranking it among Britain's largest companies. Given that British Biotech had yet to produce a drug, such enthusiasm was "nearly a miracle," says Mark Edwards, formerly one of the company's top scientists. "You need a special guy to do that."
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.